Cite

HARVARD Citation

    McCoach, C. et al. (2017). Phase I/II Study of Capmatinib Plus Erlotinib in Patients With MET-Positive Non–Small-Cell Lung Cancer. JCO precision oncology. p. . [Online]. 
  
Back to record